Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery.
Document Type
Article
Publication Date
9-18-2018
Publication Title
Annals of surgical oncology : the official journal of the Society of Surgical Oncology
Abstract
BACKGROUND: Neoadjuvant chemotherapy (NAC) is increasingly utilized to optimize survival in proximal pancreatic adenocarcinoma. However, few studies have explored the impact of NAC in distal pancreas cancer.
METHODS: Patients with resectable pancreatic adenocarcinoma of the body or tail treated with either upfront pancreatectomy or NAC followed by surgery were identified in the 2006-2014 National Cancer Database. Trends in utilization, predictors of use, and impact of NAC on overall survival were determined.
RESULTS: Of 1485 patients, 176 (11.9%) received NAC. Use of NAC increased from 9.3% in 2006 to 16.9% in 2013 [odds ratio 1.14; 95% confidence interval (CI) 1.05-1.24; p = 0.001]. NAC patients were younger, had higher clinical stage, and preoperative CA 19-9 levels (all p < 0.05). After adjustment for patient-, tumor-, and treatment-related factors, increased clinical stage was the greatest independent predictor of neoadjuvant approach (p < 0.001). On multivariable analysis, survival benefit from NAC did not reach threshold of significance (95% CI 0.66-1.04; p = 0.10) for the entire cohort. However, NAC was associated with a significant survival advantage in clinical stage III with a 51% decreased yearly risk of death (adjusted hazard ratio 0.49; 95% CI 0.25-0.98; p = 0.04). A trend towards improved survival with NAC was observed among stage IIA (p = 0.09) and IIB (p = 0.07) patients.
CONCLUSIONS: Neoadjuvant chemotherapy is associated with improved overall survival in Stage III distal pancreatic adenocarcinoma and shows promise in earlier stage disease. However, only a small percentage of patients receive NAC. Prospective evaluation of NAC in distal pancreatic adenocarcinoma is warranted based on these findings.
Clinical Institute
Cancer
Clinical Institute
Digestive Health
Department
Oncology
Department
Gastroenterology
Department
Surgery
Recommended Citation
Nelson, Daniel W; Chang, Shu-Ching; Grunkemeier, Gary; Dehal, Ahmed N; Lee, David Y; Fischer, Trevan D; DiFronzo, L Andrew; and O'Connor, Victoria V, "Resectable Distal Pancreas Cancer: Time to Reconsider the Role of Upfront Surgery." (2018). Articles, Abstracts, and Reports. 720.
https://digitalcommons.providence.org/publications/720
